Background: Intravenous (IV) iron in pregnancy is useful where oral iron is not tolerated or a rapid replenishment of iron is required.
INTRODUCTION
Iron deficiency represents the most widespread nutritional deficiency globally and is the leading cause of anaemia during pregnancy. 1 Anaemia is estimated to affect almost 40% of pregnancies worldwide and is associated with a significantly increased risk of perinatal morbidity and mortality, 1,2 including risk of low birth weight and preterm birth. 3 Further, the iron status of infants have been demonstrated to mirror that of the mother, with infants born to anaemic women at increased risk of developing iron deficiency anaemia (IDA) in the first year of life. 4 These findings are independent of birth weight or gestational age and occur despite infants born to anaemic women having normal haemoglobin status at birth. 4 Such findings are of particular interest given the previously noted association between IDA in the third trimester and impaired mental development of the offspring.
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While haemoglobin status in pregnancy has been demonstrated to be of importance, the role of iron in ameliorating such adverse outcomes in the puerperal period is less clear, although it can be postulated that if the anaemia is due to iron deficiency, replenishing iron stores should restore normal haemoglobin and lead to improved perinatal outcomes. 6 Contrary to this belief, supplementation of anaemic or non-anaemic pregnant women with iron, folic acid or both, is not associated with improvements in birth weight or gestational age. 7 Despite such uncertainty, both oral and intravenous (IV) iron are commonly utilised in clinical practice. Use of oral iron is usually considered first-line due to convenience and low cost; however, its use is limited by significant gastrointestinal side effects affecting adherence, low absorption rate, and delay in replenishing iron stores. IV iron is considered to be a useful option when treatment with oral iron has failed or when rapid replenishment is required, albeit without strong evidence supporting its role in pregnancy. Increasing use of IV iron in clinical practice has raised some concerns regarding potential harms as iron itself can lead to oxidative stress and inflammatory changes and evidence that administration of oral iron is associated with an increased risk of preterm birth in observational studies but not RCTs. 2 Multiple formulations of IV iron are available, differing on aspects such as the maximum single dose that can be administered in one sitting, the total infusion time and associated administration and medication-related costs (Table 1 ).
In light of the frequency of use in clinical practice and the multiple formulations of IV iron that are available, we undertook a systematic review to evaluate the efficacy and safety of IV iron polymaltose (IPM), iron sucrose (IS) and ferric carboxymaltose (FCM) in the management of antenatal IDA.
MATERIALS AND METHODS

Search strategy
MEDLINE, Embase and Scopus were searched for studies investigating the use of IV iron in pregnancy. The search included an obstetric concept and an IV iron concept. Terms were searched as controlled vocabulary in applicable databases and as keywords in all databases. A complete list of search terms used is presented in Appendix S1. All searches were conducted on 8 June, 2016.
Reference lists of all articles included in full-text review, as well as other review articles, were screened for additional studies.
Eligibility criteria
The study types for this review included randomised controlled trials, quasi randomised controlled trials, and observational studies, published in any language and any country. Eligible studies were those involving administration of IV iron (FCM, IPM or IS, regardless of comparator, to manage antenatal IDA. Studies only published in abstract form were not eligible for inclusion.
Data abstraction
Two independent, non-blinded authors (AQ and LEG) reviewed each title and abstract for inclusion eligibility. Full-text review was also conducted by two independent, non-blinded authors (AQ and LEG) and discrepancies were resolved through author consensus discussions. For non-English language studies included in the ‡Costs is based on dispensed price for maximum quantity which represents the base dispensed price for this medication as outlined by the Australian PBS as of June 2017 (http://www.pbs.gov.au/). The cost to the patient is dependent on whether they are eligible for a subsidy. These prices are an approximation only as there is considerable variability depending on purchasing situation or country of origin.
full-text review, the primary author (AQ) translated the contents with computer translation software, which has previously been demonstrated to be effective for systematic reviews. 
Study quality assessment
Study quality assessment was conducted by two independent, non-blinded authors (AQ and LEG) and discrepancies were resolved through author consensus discussions. To assess the in- 
RESULTS
Search results
Our search identified 1263 abstracts, comprising 1035 unique abstracts. An additional 11 articles were identified from previous systematic reviews or from checking citations of included studies and retrieved for full-text review. A total of 76 articles were included in full-text review and of these, 47 were deemed eligible for inclusion in the systematic review (Fig. 1) . The most common reason for exclusion in the full-text review was articles published in only abstract form (n = 22/29). A summary of all articles included in this review is presented in Tables 2 and 3 , while a summary of exclusion criteria and outcomes investigated in each study is presented in Appendices S2 and S3.
Overview of included studies
Of the 47 eligible studies, 21 were RCTs and 26 were observational studies. Types of IV iron formulation studied included IS (n = 2635
women; 41 studies ), FCM (n = 276 women; four studies 13, [52] [53] [54] ) and IPM (n = 164 women; three studies [55] [56] [57] ).
The majority of studies involved a comparison group of some kind including oral iron (n = 17; 36%), 11, 14, 16, 19, 24, 26, 27, 29, 31, 32, 34, 35, 37, 39, 50, 56, 57 IV iron (n = 4; 9%), 13 [14] [15] [16] 18, 20, 24, 26, 28, 31, [33] [34] [35] [36] [37] [38] [39] 41, 42, 44, 49, 50, 53 Only one study was identified that directly compared the administration of a full replacement dose of IV iron to a dose that was 300 mg less than the calculated full replacement dose. In comparing the two groups, administration of the full replacement dose was associated with a greater increase of 8 g/L 3-4 weeks after administration and 14 g/L at delivery.
28
Compared to oral iron, use of IV iron was associated with a greater increase in haemoglobin at 2-4 weeks following the infusion (median: 6 g/L; range: 1-20 g/L) 11, 16, 26, 27, 29, 31, 34, 35, 37, 39, 50, 56 and at delivery (median: 6.8 g/L; range: 6-19 g/L). 14, 16, 32, 56 When examining ferritin at 4 weeks, seven of eight studies demonstrated a greater median increase of 38 μg/L (range: 25-222 μg/L) among the group receiving IV rather than oral therapy. 11, 24, 26, 27, 35, 37, 50, 56 Only two studies reported on difference in ferritin at deliv- 
Perinatal outcomes
Few studies incorporated an investigation of perinatal outcomes.
Christoph et al. demonstrated a difference in gestational age at birth among two cohorts of women who received either IV FCM or IS (38.4 vs 39.6 weeks; P = 0.009), but this was not adjusted for important maternal characteristics that differed between the two groups. 13 Among other comparative studies, none demonstrated any statistically significant differences between groups across any perinatal outcomes investigated, including birth weight, gestational age, method of delivery, and postpartum haemorrhage. 11, 14, 16, 24, 30, 31, 37, 38, 54, 56 Notably, the small study samples included in each of these studies limited the statistical power to detect clinically relevant differences between the two groups.
Quality of life
Quality of life measures were only reported in two studies.
53,58
Both studies included assessments following delivery. Pain at injection side (n = 15; 20%), phlebitis (n = 6; 8%), fever (n = 5; 7%). 11.8 ± 1.1 g/dL (P < 0.001), IV B 8.9 ± 0.7 g/dL to 11.3 ± 0.9 g/dL (P < 0.001), IM 8.8 ± 0.9 g/dL to 10.2 ± 1.2 g/dL (P > 0.05) Hb -treatment success Delivery: IV A 80% versus IV B 70% vs IM
28% reached target Hb
Abdominal pain (n = 1); shivering/weakness within few hours of infusion (n = 2); Phlebitis at injection site (n = 3)
IBS, irritable bowel syndrome; IDA, iron deficiency anaemia; IM, intramuscular; IRR, incidence rate ratio; IS, iron sucrose; IV, intravenous; MCV, mean corpuscular volume; rhEPO, recombinant human erythropoietin. Local pain (n = 4), nausea (n = 1), flushing (n = 1), syncope (n = 5), dyspnoea (n = 2), forearm numbness (n = 1), urticaria (n = 1) and acute back pain (n = 1). (Continues) addition to improved haematological outcomes, receipt of IV iron was associated with improvements in general health (P = 0.021), improved physical energy (P = 0.016), less psychological downheartedness (P = 0.005), less clinical depression (P = 0.003), and overall improved mental health status (P < 0.001). 58 In addition, duration of breastfeeding was greater (hazard ratio (HR) for cessation: 0.70, 95% CI: 0.50-0.99; P = 0.046) among women who received IV IPM.
Cost-effectiveness
While a small number of studies reported costs of treatment, 24, 25, 36, 55, 56 none of them included a formal cost-effectiveness analysis.
Tolerability
While the way in which ADRs were monitored and reported was highly variable, the median prevalence of ADRs for IPM (2.2%; range:
0-4.5%) [55] [56] [57] was lower than FCM (5.0%; range: 0-20%) 13, [52] [53] [54] and IS (6.7%; range: 0-19.5%). 11, 13, 16, 20, [22] [23] [24] [25] 27, 31, 32, 34, 36, 38, 40, 44, 49 Across all studies, the median reported prevalence of ADRs was similar among prospective (4.5%) 11, 16, 19, 20, 22, 23, 27, 29, 31, 32, 34, 36, 38, 40, 44, 49, 53, [55] [56] [57] and retrospective (5%) 13, 52, 54 studies. Eighteen studies administered a test dose, 15, 23, [25] [26] [27] [28] [29] [30] [31] 34, 37, 39, 40, 45, 46, 50, 56 while only two studies specifically mentioned administering pre-medication. 38, 55 The median reported prevalence of ADRs was similar between studies that did (4%; range: 0-18%) and did not (6.7%; range: 0-20%) administer a test dose of iron prior to administration of the full dose.
Among the nine studies comparing IV iron to oral iron and reporting ADRs to oral therapy, in all cases ADRs were more common with oral therapy (median 33.5%; range: 27-46%) than IV therapy (median 7.5%; range: 2.2-7.5%). 14, 16, 29, 32, 34, 35, 39, 50, 56 Two studies compared IV to IM administration, noting a higher rate of ADRs in the IM group (27% and 24%) compared with the IV group (3% and 8%).
25,38
The prevalence of moderate or severe adverse reactions requiring treatment or discontinuation of IV iron was slightly higher in observational studies (13/1352; 9.6 per 1000 women; n = 20 studies) 12,13,19,20,22,23,32,33,40,41,44- [11] [12] [13] [14] [15] [16] 19, 20, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [44] [45] [46] [47] [49] [50] [51] or FCM (1/276; 3.6 per 1000).
13,52-54
Risk of bias
Included studies were noted to be of variable methodological quality (Appendices S5 and S6). One of the key challenges consistent to RCTs and observational studies relates to blinding of subjects and clinicians to the intervention, but it is unclear what impact lack of blinding to IV iron administration may have on evaluated outcomes. One quarter (5/21) of the included RCTs were considered to be at high risk of bias in at least one domain. Most common sources of possible bias include concerns related to selective reporting (eg perinatal outcomes evaluated but not published) and incomplete outcome data (eg high loss to follow up).
Observational studies were assessed as being at greater risk of bias, with 12 of 26 studies identified as being at high risk of bias in at least one domain. These most often related to concerns regarding selection of participants, inadequate adjustments for potential confounders, incomplete outcome data and selective outcome reporting. Overall, the incomplete manner in which many studies were described meant that many aspects were regarded as unclear risk of bias. Further, while a small number of studies were registered in an international clinical trials registry, none of them had a published protocol available, making it difficult to evaluate aspects such as incomplete outcome data and selective reporting which were a concern for a subset of studies.
DISCUSSION
Our systematic review finds that use of IV iron during pregnancy is associated with significant improvements in haematological pa- observational studies may be prone to more bias than RCTs, they provide useful information on the incidence/prevalence of adverse events related to IV iron, and potential usefulness of different IV infusion regimens.
Despite the comprehensive nature of our systematic review, several limitations bear consideration. First, significantly variability was evident across all included studies, with differences in study population, trial methods including dosing regimens, timing of assessment and outcome evaluation. Such heterogeneity has been observed in previous systematic reviews of iron supplementation in pregnancy, 65 precluding meta-analytical techniques.
Second, a large number of studies (50% overall, and 70% of RCTs)
were undertaken in low resources settings, where study participants were more likely to have moderate or severe anaemia, and does not necessarily reflect practice in higher-resource settings where IV iron may be utilised in the management of mild anaemia. In low-resource settings, where moderate to severe anaemia is more common, the benefits of IV iron administration may prove to be much greater compared with that in higher-resource settings where IV iron is commonly utilised in the management of mild anaemia or non-anaemic iron deficiency. 66 A systematic review of routine oral iron supplementation in pregnancy identified that implementation of routine supplementation recommendations were likely to produce heterogenous results depending on the populations' background risk for adverse pregnancy outcomes and the same could be expected for IV iron. 67 In conclusion, given the noted negative impacts of moderate and severe anaemia on adverse maternal and neonatal outcomes, high-quality data on the effect of IV iron repletion on ameliorating adverse outcomes are necessary for informing clinical practice. Yet, our systematic review has found that the evidence base from a combination of randomised and observational studies is limited, with a noted focus on evaluation of haematological response to treatment and maternal tolerability of infusions, with very limited data on clinically relevant outcomes.
There is no clear evidence that administration of IV iron is associated with improved perinatal outcomes, and only limited evidence that administration is associated with improved quality of life measures. This review highlights a number of substantive gaps in the primary literature, including insufficient evidence on levels of anaemia requiring treatment with IV iron, optimal gestational timing of administration, and IV iron dosing regimens.
Currently, considerable resources are utilised in the diagnosis and treatment of iron deficiency anaemia, despite a lack of evidence of clear benefit and potential harms. As such, widespread use of IV iron in pregnancy should be discouraged in favour of adequately controlled clinical trials with appropriate inclusion criteria and evaluation of clinical outcomes.
